MétaCan
Menu
Back to cohort
Record W4411686992 · doi:10.1093/jac/dkaf184

Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort

2025· article· en· W4411686992 on OpenAlexaff
Roberta Gagliardini, S De Benedittis, Alessandro Tavelli, Giuseppe Lapadula, Valentina Mazzotta, Elena Bruzzesi, Adriana Cervo, Giorgia Carrozzo, Annalisa Saracino, Stefano Rusconi, Giulia Marchetti, Francesca Ceccherini‐Silberstein, Andrea Antinori, Antonella d’Arminio Monforte, Camilla Muccini, Antonella d’Arminio Monforte, Spinello Antinori, Antonella Castagna, Roberto Cauda, Giampaolo Perri, Enrico Girardi, R Iardino, Adriano Lazzarin, C Mussini, Eugenia Quirós-Roldán, Loredana Sarmati, Barbara Suligoi, F von Schloesser, P. Viale, Antonella Cingolani, Alessandro Cozzi‐Lepri, Antonio Di Biagio, Andrea Gori, Sergio Lo Caputo, G Marchetti, Franco Maggiolo, Massimo Puoti, Carlo Federico Perno, Carlo Torti, Alessandra Bandera, Stefano Bonora, Andrea Calcagno, Diana Canetti, A Cervo, Paola Cinque, Roberta Gagliardini, Nicola Gianotti, Giovanni Guaraldi, Simone Lanini, Miriam Lichtner, Alessia Lai, Giordano Madeddu, Vincenzo Malagnino, Annalisa Mondi, Silvia Nozza, Stefania Piconi, Carmela Pinnetti, Roberto Rossotti, Maria Mercedes Santoro, Vincenzo Spagnuolo, Nicola Squillace, Valentina Svicher, Lucia Taramasso, Alessandra Vergori, Iuri Fanti, M Giotta, Cécilia Marelli, A Rodano, Massimo Cernuschi, L Cosmaro, A Perziano, Valeria Calvino, Danilo Russo, M Farinella, Nicoletta Policek, V L Del Negro, Matteo Augello, Silvia Carrara, Silvia Graziano, Gennaro Prota, S Truffa, Donatella Vincenti, Roberta Rovito, Hossein Sadeghi, Andrea Giacometti, Andrea Costantini, V Barocci, Carmen Rita Santoro, Eugenio Milano, Laura Comi, Claudia Suardi, Leonardo Badia, Silvia Cretella, E M Erne, A Pieri, Emanuele Focà, B Menzaghi, C Abeli, Luchino Chessa, Francesco Pes, Paolo Maggi, Loredana Alessio, Giuseppe Nunnari, Benedetto Maurizio Celesia, Jacopo Vecchiet, Katia Falasca, Angelo Pan, Sarah Dal Zoppo, Daniela Segala, Filippo Bartalesi, Cecilia Costa, Sergio Ferrara, Matteo Bassetti, Emanuele Pontali, Sophie Blanchi, Nicoletta Bobbio, Cosmo Del Borgo, R. Marocco, G Mancarella, Chiara Molteni, G Canavesi, Giovanni Francesco Pellicanò, Gloria Montenegro Rizzardini, Valeria Bono, Maria Vittoria Cossu, Riccardo Lolatto, M C Moioli, Laura Pezzati, S Diotallevi, Camilla Tincati, M Menozzi, Paolo Bonfanti, Vincenzo Sangiovanni, Ivan Gentile, Vincenzo Esposito, Nicola Coppola, Francesco Maria Fusco, Giovanni Di Filippo, Vincent Rizzo, N Sangiovanni, Salvatore Martini, Anna Maria Cattelan, D Leoni, Antonio Cascio, Marcello Trizzino, Daniela Francisci, Elisabetta Schiaroli, Giustino Parruti, Federica Sozio, D Messeri, Sara Irene Bonelli, C Lazzaretti, R Corsini, Claudio Maria Mastroianni, Alessandra Latini, Ilaria Mastrorosa, Silvia Lamonica, M Capozzi, Marta Camici, Ivano Mezzaroma, Marco Rivano Capparuccia, Giancarlo Iaiani, C Stingone, L Gianserra, Jessica Paulicelli, Maria Maddalena Plazzi, G d’Ettore, Marisa Fusto, I Coledan, Andrea De Vito, Massimiliano Fabbiani, Francesca Montagnani, Alfredo Franco‐Obregón, Rosario Vecchio, Giancarlo Orofino, Guido Calleri, Giacomo Accardo, Carlo Tascini, Alejandra Londero, Giuliana Battagin, S Nicolè, Giulio Starnini, Serena Dell’Isola

Bibliographic record

VenueJournal of Antimicrobial Chemotherapy · 2025
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsTula Foundation
FundersViiV HealthcareGilead Sciences
KeywordsRilpivirineDiscontinuationMedicineHuman immunodeficiency virus (HIV)CohortInternal medicineIntensive care medicinePharmacologyAntiretroviral therapyVirologyViral load

Abstract

fetched live from OpenAlex

BACKGROUND: Phase 3 studies have shown long-acting (LA) cabotegravir/rilpivirine to be effective and tolerable as maintenance therapy in people with HIV (PWH). However, real-life data on their effectiveness are limited. METHODS: All PWH enrolled in the Icona Cohort who started LA cabotegravir/rilpivirine with HIV-RNA < 50 copies/mL were included. Times to treatment discontinuation (TD) and to virological failure (VF50, two consecutive HIV-RNA >50 copies/mL or one >1000 copies/mL followed by ART switch) were estimated by the Kaplan-Meier method. Cox regression models, adjusted for age, sex and mode of HIV transmission and stratified by the centre, were employed. RESULTS: Overall, 583 PWH started LA cabotegravir/rilpivirine. Six VF50 were observed, with a 1 year estimated cumulative probability of virological failure of 1.2% (95% CI, 0.5%-3.0%). Resistance-associated mutations for rilpivirine and cabotegravir were detected in 3/4 and 4/4 participants with VF50, respectively, for which the genotypic resistance test was performed.The 1 year cumulative probability of TD was 11.4% (95% CI, 8.6%-14.9%), mainly caused by toxicity/adverse events (73.2%). Multivariable analysis identified heterosexual intercourse and IV drug use as significant risk factors for TD compared with MSM. CONCLUSIONS: This analysis demonstrated the short-term effectiveness of cabotegravir/rilpivirine in a real-life setting showing minimal incidence of virological failure but a notable probability of discontinuation due to toxicity or adverse events.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.006
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.008
Threshold uncertainty score0.016

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.006
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.012
GPT teacher head0.270
Teacher spread0.259 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations11
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Antimicrobial ChemotherapySame topicHIV/AIDS drug development and treatmentFrench-language works237,207